Dr. Howard Shulman
Dr. Howard Shulman
I specialize in
I have been in practice
My answers and insights have
Helped 20 people
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I was educated and trained at
Medical / Graduate School
University of California, Los Angeles David Geffen School of Medicine
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
Blood., Aug;120(7):1398-408 (2012)
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
Biol. Blood Marrow Transplant., Jul;16(7):1005-17 (2010)
Iron overload, hematopoietic cell transplantation, and graft-versus-host disease.
Leuk. Lymphoma., Oct;50(10):1566-72 (2009)
Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis.
PLoS ONE., 4(7):e6203 (2009)
Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome.
Bone Marrow Transplant., Oct;44(7):441-7 (2009)
Transplantation of allogeneic T cells alters iron homeostasis in NOD/SCID mice.
Blood., Feb;113(8):1841-4 (2009)
Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?
PLoS ONE., 3(1):e1452 (2008)
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
Blood., Aug;110(4):1379-87 (2007)
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.
Biol. Blood Marrow Transplant., Jan;12(1):31-47 (2006)
Prevention of Fas-mediated hepatic failure by transferrin.
Lab. Invest., Mar;84(3):342-52 (2004)
Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: low-dose TBI does not prevent sensitization.
Biol. Blood Marrow Transplant., 8(7):360-7 (2002)
Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease).
Semin. Liver Dis., Feb;22(1):27-42 (2002)
Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.
Blood., Apr;99(7):2310-4 (2002)
Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis.
Hepatology., Dec;32(6):1265-71 (2000)
The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry.
Am. J. Clin. Pathol., Oct;112(4):513-23 (1999)
Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation.
Am. J. Clin. Pathol., Jul;110(1):84-94 (1998)
Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis.
Bone Marrow Transplant., Dec;20(12):1081-6 (1997)
Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients.
Transplantation., Apr;59(7):1015-22 (1995)
Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms.
Hepatology., May;19(5):1171-81 (1994)
Two cases of transfusion-associated graft-vs-host disease after open heart surgery.
Arch Dermatol., Nov;128(11):1503-6 (1992)
Dr. Howard Shulman M